Trial Profile
Central nervous effects of Exenatide i.v. vs. NaCl 0.9% on regulation of hunger and satiety in obesity and type 2 diabetes: an fMRI study. Amendment 1: increase of dosage.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2019
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms Neuroimaging and Obesity
- 06 Jul 2012 Actual initiation date (13 Jan 2010) added as reported by German Clinical Trials Register.
- 21 Apr 2012 Planned number of patients changed from 20 to 40 as reported by European Clinical Trials Database.
- 21 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2007-007970-47).